CWP
HRTX icon

Cyndeo Wealth Partners’s Heron Therapeutics HRTX Stock Holding History

Cyndeo Wealth Partners’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-248,087
Closed -$323K – 494
2025
Q4 		$323K Hold
248,087
– – 0.02% 387
2025
Q3 		$313K Hold
248,087
– – 0.02% 381
2025
Q2 		$514K Buy
+248,087
New +$507K 0.03% 302

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Cyndeo Wealth Partners's HRTX Position: Q1 2026 in Review

Cyndeo Wealth Partners sold out of Heron Therapeutics (HRTX) in Q1 2026, closing a stake of 248,087 shares — an estimated $323K sold.

Cyndeo Wealth Partners first reported a position in HRTX in Q2 2025 and held it in 3 quarters. The position peaked at $514K in Q2 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Cyndeo Wealth Partners reported no remaining Heron Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Cyndeo Wealth Partners sold 248,087 Heron Therapeutics shares in Q1 2026, an estimated $323K.
  • Cyndeo Wealth Partners first reported a position in Heron Therapeutics in Q2 2025 and held it in 3 quarters.
  • Cyndeo Wealth Partners's Heron Therapeutics position peaked at $514K in Q2 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Cyndeo Wealth Partners's 13F filing for Q1 2026, filed 13 Apr 2026.